Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 231-239

  Zhou, Jiaqiang ^a   Wu, Jiahua ^a   Zheng, Fenping ^a   Jin, Mengshi ^a   Li, Hong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Cholesterol; Glucagon like peptide 1; Mammalian target of rapamycin; cells

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; CHOLESTEROL; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; LIPOTOXICITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCIENCE; STAINING; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INSULINOMA; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CHOLESTEROL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULINOMA; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84924103173     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12177     Document Type: Article

References (40)

1. Danaei G, Finucane MM, Lu Y etal. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011; 378: 31-40.
2. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003; 52: 581-587.
3. Unger RH. Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144: 5159-5165.
4. Prentki M, Corkey BE. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM. Diabetes. 1996; 45: 273-283.
5. Poitout V, Robertson RP. Secondary beta-cell failure in type 2 diabetes: A convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002; 143: 339-342.
6. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995; 44: 863-870.
7. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: A novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007; 56: 2328-2338.
8. Zhao YF, Wang L, Lee S etal. Cholesterol induces mitochondrial dysfunction and apoptosis in mouse pancreatic beta-cell line MIN6 cells. Endocrine. 2010; 37: 76-82.
9. Lu X, Liu J, Hou F etal. Cholesterol induces pancreatic beta cell apoptosis through oxidative stress pathway. Cell Stress Chaperones. 2011; 16: 539-548.
10. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987; 84: 3434-3438.
11. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropichormone glucagon-like peptide-1(7-37). Nature. 1993; 361: 362-365.
12. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulinsecretion. Diabetes. 2002; 51 (Suppl. 3): S434-442.
13. Fontes G, Hagman DK, Latour MG, Semache M, Poitout V. Lack of preservation of insulin gene expression by a glucagon-like peptide 1agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model ofglucolipotoxicity. Diabetes Res Clin Pract. 2010; 87: 322-328.
14. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab. 2004; 15: 27-33.
15. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002; 359: 824-830.
16. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999; 140: 5356-5363.
17. Neumiller JJ, Sonnett TE, Wood LD, Setter SM, Campbell RK. Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2010; 3: 215-226.
18. Cunha DA, Ladriere L, Ortis F etal. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009; 58: 2851-2862.
19. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004; 47: 806-815.
20. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology. 2003; 144: 1444-1455.
21. Brunham LR, Kruit JK, Pape TD etal. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response tothiazolidinedione treatment. Nat Med. 2007; 13: 340-347.
22. Lee AK, Yeung-Yam-Wah V, Tse FW, Tse A. Cholesterol elevation impairs glucose-stimulated Ca(2+) signaling in mouse pancreatic beta-cells. Endocrinology. 2011; 152: 3351-3361.
23. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005; 9: 59-71.
24. Tuttle RL, Gill NS, Pugh W etal. Regulation of pancreatic beta-cell growth and survival by the serine/threonineprotein kinase Akt1/PKBalpha. Nat Med. 2001; 7: 1133-1137.
25. Dickson LM, Rhodes CJ. Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: A role for protein kinase B in the Akt. Am J Physiol Endocrinol Metab. 2004; 287: E192-198.
26. Elghazi L, Balcazar N, Bernal-Mizrachi E. Emerging role of protein kinase B/Akt signaling in pancreatic beta-cell mass and function. Int J Biochem Cell Biol. 2006; 38: 157-163.
27. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cellturnover and function. Diabetes. 2001; 50: 69-76.
28. Avruch J, Hara K, Lin Y etal. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006; 25: 6361-6372.
29. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006; 3: 393-402.
30. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003; 10: 1165-1177.
31. Chen L, Xu B, Liu L etal. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest. 2010; 90: 762-773.
32. Faghiri Z, Bazan NG. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis. Exp Eye Res. 2010; 90: 718-725.
33. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect. Am J Physiol Endocrinol Metab. 2003; 285: E701-707.
34. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia. 2004; 47: 478-487.
35. Farilla L, Hui H, Bertolotto C etal. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002; 143: 4397-4408.
36. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: Role of protein kinase B. Diabetologia. 2005; 48: 1339-1349.
37. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes. 2004; 53 (Suppl. 3): S225-232.
38. Van de Velde S, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci USA. 2011; 108: 16876-16882.
39. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer. 2009; 115: 3887-3896.
40. Itamochi H, Oishi T, Shimada M etal. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin Cancer Res. 2011; 17: 4742-4750.